Drug Profile
Affitope PD03
Alternative Names: Affitope-PD03; Affitope-PD03A; PD03; PD03ALatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator AFFiRiS
- Class Antiparkinsonians; Peptide vaccines
- Mechanism of Action Alpha-synuclein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple system atrophy; Parkinson's disease
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Multiple system atrophy(Early-stage disease) in France (SC, Injection)
- 27 Jul 2021 AC Immune acquires Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs from AFFiRiS
- 10 Sep 2020 Affitope PD03 is still in phase I trial for Multiple system atrophy in France